Market Movers rounded up the best reactions from investors and analysts on Biogen . The experts discussed the biotech company after the Food and Drug Administration approved its Alzheimer’s treatment Leqembi , paving the way for broader Medicare coverage. The drug slowed cognitive decline in trials, but poses risks of brain swelling and bleeding and comes with a $26,500 per year price tag. Biogen collaborated with Japanese pharmaceutical company Eisai to make Leqembi. Despite the approval, Biogen shares slid more than 3% by Friday’s market close and are down nearly 10% over the past month.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Discussion about this post